What is Bactobio?
Bactobio is a London-based biotechnology firm at the forefront of synthetic biology innovation. The company employs cutting-edge technologies, including next-generation sequencing and machine learning, to cultivate microorganisms that were previously inaccessible. This exclusive access to a vast bioresource enables Bactobio to identify and develop novel chemical and biological products for critical sectors such as pharmaceuticals, agriculture, and bioderived chemicals. The company's strategic positioning in the UK facilitates its research and development efforts.
How much funding has Bactobio raised?
Bactobio has raised a total of $7.3M across 1 funding round:
Other Financing Round
$7.3M
Other Financing Round (2022): $7.3M with participation from Bridford Group
Key Investors in Bactobio
Bridford Group
Bridford Group is an investment entity that deploys proprietary capital across diverse sectors including technology and biotech, with a focus on founder-led businesses in Europe that exhibit long-term growth potential and positive societal impact.
What's next for Bactobio?
With this major enterprise-level funding, Bactobio is poised for significant expansion and further technological development. The strategic investment signals confidence in the company's unique approach to microbial discovery and its potential to disrupt multiple industries. Future endeavors will likely focus on scaling its proprietary cultivation platforms, accelerating product development pipelines, and forging new partnerships across its target markets. This capital infusion is expected to fuel Bactobio's growth trajectory and solidify its position as a leader in the synthetic biology space.
See full Bactobio company page
